Sargassum pallidum reduces inflammation to exert antidepressant effect by regulating intestinal microbiome and ERK1/2/P38 signaling pathway

Immune inflammation is one of the main factors in the pathogenesis of depression. It is an effective and active way to find more safe and effective anti-inflammatory depressant drugs from plant drugs. The purpose of this study is to explore the potential of marine plant (Haihaozi, HHZ) in the preven...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2024-07, Vol.15, p.1424834
Main Authors: Su, Dan, Li, Qianmin, Lai, Xin, Song, Yonggui, Li, Huizhen, Ai, Zhifu, Zhang, Qi, Shao, Wenxiang, Yang, Ming, Zhu, Genhua
Format: Article
Language:English
Subjects:
antidepressant
gut microbiota
inflammation
network pharmacology
Pharmacology
sargassum pallidum
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune inflammation is one of the main factors in the pathogenesis of depression. It is an effective and active way to find more safe and effective anti-inflammatory depressant drugs from plant drugs. The purpose of this study is to explore the potential of marine plant (Haihaozi, HHZ) in the prevention and treatment of depression and to explain the related mechanism. Phytochemical analysis showed that alkaloids, terpenes, and organic acids are the main constituents. and activity studies showed the anti-neuroinflammatory and antidepressant effect of , furthermore, confirmed that 7-Hydroxycoumarin, Scoparone, and Kaurenoic Acid are important plant metabolites in Sargasum pallidum for anti-neuroinflammation. Mechanism exploration showed that inhibition of ERK1/2/p38 inflammatory signaling pathway contributing to the antidepressant effect of in reducing intestinal inflammatory levels. This study confirmed the value of and its rich plant metabolites in anti-inflammatory depression, providing a new choice for the follow-up research and development of antidepressant drugs.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2024.1424834